Evoke PharmaEVOK
EVOK
About: Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Employees: 4
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
19.1% less ownership
Funds ownership: 44.5% [Q2] → 25.4% (-19.1%) [Q3]
31% less funds holding
Funds holding: 16 [Q2] → 11 (-5) [Q3]
51% less capital invested
Capital invested by funds: $2.02M [Q2] → $995K (-$1.03M) [Q3]
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 8
Research analyst outlook
We haven’t received any recent analyst ratings for EVOK.
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, underscores its commitment to patients and healthcare providers managing gastroparesis in light of FDA's recent update regarding domperidone supply.
Neutral
GlobeNewsWire
2 weeks ago
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent applications by the United States Patent and Trademark Office, further expanding the company's robust intellectual property estate for its innovative GIMOTI® (metoclopramide) nasal spray.
Neutral
Business Wire
1 month ago
InvestCloud to Partner with Evoke Advisors to Transform Their Digital Experience
LOS ANGELES--(BUSINESS WIRE)--InvestCloud, a global leader in wealth technology, announced a strategic partnership with Registered Investment Adviser (RIA) Evoke Advisors (Evoke) to transform their digital experience. With InvestCloud's Client Experience, Evoke's clients, prospects, and third-party intermediaries will benefit from a significantly elevated and differentiated branded experience that features powerful, data-driven visualizations catering to the firm's exclusive clientele. As the t.
Neutral
GlobeNewsWire
1 month ago
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year
Positive
Proactive Investors
1 month ago
Ladbrokes and William Hill owners Entain and Evoke jump on Budget relief
Shares in bookmakers galloped higher after the UK Budget, led by Ladbrokes and Coral owner Entain PLC (LSE:ENT), which rose over 8%, and William Hill owner Evoke PLC, rising 12%. Paddy Power and Betfair owner Flutter Entertainment PLC (LSE:FLTR) also rose 6%.
Positive
Invezz
1 month ago
Evoke Pharma stock surges over 100%—here's why
Evoke Pharma Inc (NASDAQ: EVOK) opened well over 100% up on Monday after reporting positive results for a study on its metoclopramide nasal spray. The pharmaceutical company said its nasal spray known broadly as GIMOTI offers substantial benefits to patients of diabetic gastroparesis (DGP) on GLP-1 receptor agonists.
Neutral
GlobeNewsWire
1 month ago
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced upcoming poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, held from October 25-29, 2024.
Neutral
GlobeNewsWire
2 months ago
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors
SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced the appointment of Ben Smeal to serve on the Company's Board of Directors effective October 18, 2024. This appointment fulfills a condition set as part of the company's most recent financing by Nantahala Capital Management.
Positive
Proactive Investors
2 months ago
Evoke reports first quarter of growth in over two years
William Hill and 888 owner Evoke PLC (LSE:EVOK) has reported a 3% increase in revenue to £417 million for the third quarter of 2024, compared to the same period last year. It highlighted that this marks its first quarter of year-on-year growth since Q1 2022, and its progress was driven by market share gains in key international markets.
Negative
Proactive Investors
2 months ago
Bookmakers Entain, Flutter, Evoke and Rank tumble on new gambling tax reports
Shares in listed bookmakers Entain PLC (LSE:ENT), Flutter Entertainment PLC (LSE:FLTR) and Evoke PLC (LSE:EVOK) tumbled on the back of news that the UK government might target the sector in this month's Budget. HM Treasury could hit the gambling industry with a £3 billion tax raid, it was reported at the weekend, as Rachel Reeves looks for ways to help fill the £22 billion 'black hole' in the public finances.
Charts implemented using Lightweight Charts™